In a partnership with Medable, a center at the university discovered costs linked to investing in decentralized studies far outweigh the eventual benefits.
A representative from IQVIA discusses the particulars of the US agency’s new draft document and shares what it might mean for clinical trial data evaluation.
A leader from Elligo Health Research (a SCOPE 2022 exhibitor ) discusses flaws in traditional recruitment approaches and offers up some fresh new ideas.
A leader from the RBQM solutions specialists offers a preview of his SCOPE 2022 presentation on tools suited to decentralized trial design and management.
The upcoming industry event offers attendees (in-person and virtual) a range of opportunities to learn, connect, and innovate, according to an organizer.
One of the finalists for the 2022 Participant Engagement Award (saluting patient recruitment and retention solution) will be announced as winner at SCOPE.
An expert from the CRO discusses unique challenges associated with running clinical trials that stretch across national boarders and how to conquer them.
The agency has given the go-ahead on an IND application for a study evaluating Ananda Scientific’s Nantheia ATL5, a candidate for treating opioid use disorder.
The CRO's work with La Jolla Institute for Immunology, centered on a unique mouse model, is intended to increase understanding of how the COVID-19 virus operates.
An expert from patient solutions firm Trialbee discusses how the social media firm's recent ban on targeted advertising might impact patient recruitment.
The Medicines and Healthcare Products Regulatory Agency has released proposals to bolster trials legislation, asking citizens for input on the suggestions.
Regulatory bodies in the European Union have launched an initiative to develop the region as a focal point for clinical research and to better integrate clinical research in the European health system.
Blue Note Therapeutics has announced the status has been granted to BNT200, a device to treat anxiety and depression in acute myeloid leukemia patients.
The researchers, in studying how polyps morph into colorectal cancer, have set a path for improved surveillance of the disease, harnessing precision medicine.
According to the company’s 12th Annual Pharmaceutical Innovation Report, pharmaceutical R&D return on investment has climbed to its highest peak since 2014.
Two experts from the CRO discuss artificial intelligence, machine language processing, and other analytical tools that can be useful in data management.
With the amount of available data increasing and technology evolving, says a company leader, the job of data manager is more demanding than ever before.
A leader from the company discusses challenges in control labs and shares how a new solution aims to clear some key obstacles to greater effectiveness.
The pharma firm and collaborator Molecular Partners reported positive data out of their Phase II study for ensovibep, an antiviral for treating the virus.
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern University’s Shirley Ryan AbilityLab.
The collaboration will center on development of unique data sets, which could be used in helping promote better understanding of aspects of human health.
Joining with a noted research foundation, the group is aiming for earlier detection and treatment of the disease, which hits nearly 500K people annually.
This month’s news on mergers and acquisitions, hires, and other developments includes notable firms like Altasciences, Protocol First, WuXi STA, and more.
An AI expert discusses progress in the field, gaps in understanding, and how predictive modeling and other advanced analytical tools could be put to use.
A forward-looking report from company experts includes a breakdown of the top trends to watch for in pharmaceutical development and in healthcare overall.
A leader from the clinical trial technology company says that insights gained during the recent pandemic could be helpful in realizing future improvements.
It has been a pleasure for the OSP team to connect with a long list of fascinating industry minds and share the stories; here are a few of our favorites.
OSP’s list of the year’s most-read stories shows readers are interested in M&A activities, new drug candidates, COVID-19 developments, and other hot news.
The organization is working to give oncology professionals the chance to hear directly from patients about their unique experiences, concerns, and hopes.
A leader from Oracle Health Sciences shares insights on how drug development and research pros collaborated to overcome formidable challenges this year.
This month’s collaborations, tech partnerships, new facilities, and other happenings includes news from Flywheel, Medable, Veeva, and other organizations.
According to an expert from the clinical insights company, prejudice in AI can impact patient outcomes as well as the ability to develop effective treatments.
The company has released a survey of cancer doctors; 83% of those polled believe real-world data is crucial to accelerating cancer research and treatment.
Professionals from various corners of the life-sciences field share views on significant challenges of 2021, bright spots, and what to look for in 2022.
While the pandemic saw many trials to shift to decentralized midstream, an expert from the trial tech firm suggests a ground-up design approach is preferable.
A leader from the Decentralized Trials and Research Alliance offers perspective on the tools, technology, and thinking needed to advance clinical research.
The Parkinson’s Progression Markers Initiative, built using Evidation Health’s research platform, aims to triple enrollment and recruit online participants.
The artificial intelligence-driven drug discovery company has dosed its first healthy volunteer in a trial for a candidate to treat idiopathic pulmonary fibrosis.
According to the company, the latest Phase II/III study results show its novel oral treatment candidate is effective in reducing hospitalizations and deaths.
Novartis has introduced its T-Charge platform at ASH 2021, which it says will serve as the foundation for various new investigational CAR-T cell therapies in its pipeline.
The healthcare company has gifted $1m to form a scholarship fund for students headed toward careers in clinical research, with the aim of increasing diversity.
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
A leader from the advanced data and artificial intelligence specialist suggests ways to advance data collection through new tools, techniques, and thinking.
The US Department of Justice has charged a former CFO and a former head of corporate communications for allegedly conducting an insider trading scheme.
Sited in Pennsylvania, the excipients specialist’s new facility reportedly will work toward advancing drug delivery research and boosting speed to market.
According to a leader from Cytoreason, AI isn’t necessarily the best or only tool suited to discover new and novel therapies—it might take a human touch.
According to a leader from the virtual engagement solutions company, gaps in trial communications can be improved with the intelligent use of technology.
A survey on perceptions toward the decentralized clinical trial format, conducted by Climedo, shows the industry is aware of the benefits but faces barriers
The organizations have issued an in-depth look on issues impacting inclusivity, why change is needed, and potential solutions for increasing trial diversity.
An expert from the contract research organization discusses the impact decentralized trials have had on the industry, and how that transformation is likely to continue.
